Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Intravenous Administration of 12 mg [14C]Copanlisib (BAY 80-6946) in Healthy Male Subjects

Trial Profile

Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Intravenous Administration of 12 mg [14C]Copanlisib (BAY 80-6946) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Copanlisib (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 12 Mar 2016 Results assessing biotransformation and disposition presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 22 Jul 2014 Planned End Date changed from 1 May 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top